GlassScriptPhysician profile
Diana Lynn Bitner
NPI 1457308488
$57,577.31
in general payments reported to CMS, 2019-2025
18 companies · $9,614 in 2025
The $9,614 reported for 2025 was more than what 99% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $30K · 2020: $2,176 · 2021: $805 · 2022: $2,851 · 2023: $536 · 2024: $12K · 2025: $9,614.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $17K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,009 · Food and Beverage: $1,454 · Travel and Lodging: $1,300 · Education: $231.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $17,098.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,009.00 |
| Food and Beverage | $1,454.11 |
| Travel and Lodging | $1,300.02 |
| Education | $231.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Therapeuticsmd, INC. | $31,947.83 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $23,194.15 | 2021-2025 | |
| Astellas Pharma US INC | $715.63 | 2022-2025 | Veozah |
| Lupin INC. | $600.00 | 2021 | |
| Cosette Pharmaceuticals INC. | $192.74 | 2025 | Vyleesi |
| Novo Nordisk INC | $191.31 | 2022-2025 | Wegovy |
| Echosens North America, INC. | $185.47 | 2023 | Fibroscan |
| Pfizer INC. | $112.22 | 2023-2025 | |
| Abbvie INC. | $102.00 | 2022-2025 | Lo Loestrin Fe, Orilissa |
| Mayne Pharma Commercial LLC | $70.50 | 2025 | |
| Lilly USA, LLC | $56.93 | 2023-2024 | Zepbound |
| Amag Pharmaceuticals, INC. | $51.29 | 2019 | |
| Hologic Sales and Service, LLC | $44.69 | 2025 | Sonata Sonography-Guided Transcervical Fibroid Ablation System, Myosure Tissue Removal Device |
| Tactile Systems Technology INC | $34.63 | 2024 | Flexitouch Plus, Entre Plus |
| Biohaven Pharmaceutical Holding Company LTD. | $23.66 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $20.49 | 2021 | |
| Abbott Laboratories | $19.71 | 2024 | Freestyle Libre 3 |
| Vivus LLC | $14.06 | 2023 | Pancreaze |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diana Bitner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.